翰森制药新型抗体药物获临床试验批准

财中社
17 Dec 2024

  财中社12月17日电翰森制药(03692)发布自愿公告,宣布其自主研发的新型抗体–药物偶联物注射用HS-20110于2024年12月16日获得中国国家药品监督管理局签发的药物临床试验批准通知书。该临床试验计划用于晚期实体瘤的治疗。

  此次批准标志着公司在新药研发方面的重要进展,为后续的临床试验奠定了基础。公司将继续推进该项目,期望能为晚期实体瘤患者提供新的治疗选择。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10